1801.XHKG Overview
Upcoming Projects (1801.XHKG)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (1801.XHKG)
-
A Third Look: Discussing the current treatment landscape and the potential of Mazdutide, a weight-loss drug currently in development by Innovent for patients with obesity
Ticker: 1801.XHKG
Executed On: Mar 12, 2024 at 04:30 PM EDT -
A Second Look: Discussing the current treatment landscape and the potential of Mazdutide, a weight-loss drug currently in development by Innovent for patients with obesity
Ticker: 1801.XHKG
Executed On: Mar 08, 2024 at 12:00 PM EST -
Discussing the current treatment landscape and the potential of Mazdutide, a weight-loss drug currently in development by Innovent for patients with obesity
Ticker: 1801.XHKG
Executed On: Feb 23, 2024 at 01:30 PM EST -
A third look: Discussing the phase 3 CREDIT clinical trials of Sintbilo (Tafolecimab Injection) in patients with primary hypercholesterolemia and mixed dyslipidemia.
Ticker: 1801.XHKG
Executed On: Sep 07, 2023 at 06:00 PM EDT -
A second look: Discussing the phase 3 CREDIT clinical trials of Sintbilo (Tafolecimab Injection) in patients with primary hypercholesterolemia and mixed dyslipidemia.
Ticker: 1801.XHKG
Executed On: Aug 31, 2023 at 12:30 PM EDT -
Discussing the phase 3 CREDIT clinical trials of Sintbilo (Tafolecimab Injection) in patients with primary hypercholesterolemia and mixed dyslipidemia.
Ticker: 1801.XHKG
Executed On: Aug 25, 2023 at 05:00 PM EDT
Upcoming & Overdue Catalysts (1801.XHKG)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (1801.XHKG)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
